Related Experiment Video
Updated: Apr 30, 2026
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
Published on: June 19, 2018
Optimizing NKT cell ligands as vaccine adjuvants.
Leandro J Carreño1, Shalu Sharma Kharkwal, Steven A Porcelli
1Department of Microbiology & Immunology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA.
Invariant natural killer T cells (iNKT cells) can be activated by specific glycolipids. This review highlights their potential to enhance vaccines and immunotherapies for infections and cancers.
Area of Science:
- Immunology
- Cellular immunology
- Immunotherapy
Background:
- Invariant natural killer T (iNKT) cells bridge innate and adaptive immunity.
- iNKT cells recognize glycolipid antigens presented by CD1d molecules.
- Synthetic glycolipids, like α-galactosylceramides, are potent iNKT cell agonists.
Purpose of the Study:
- To review evidence supporting the use of iNKT cell-activating glycolipids.
- To explore applications in enhancing immune responses for vaccines and immunotherapies.
Main Methods:
- Review of basic, preclinical (animal), and clinical (human) studies.
- Analysis of immune responses modulated by iNKT cell activation.
Main Results:
- Preclinical studies demonstrate glycolipid efficacy in augmenting immune responses.
- Early clinical trials show promising results for iNKT cell-based strategies.
- iNKT cell activation shows potential in vaccination and cancer immunotherapy.
Conclusions:
- iNKT cell-activating glycolipids represent a promising strategy for improving vaccines.
- These glycolipids offer novel therapeutic avenues for infectious diseases and cancers.
More Related Videos
12:53Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
Published on: March 16, 2022
08:15In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D
Published on: December 9, 2022